As both the volume and diversity of specimens required for clinical development continue to grow, oncology research is increasingly reliant on robust biorepository strategies.
With cancer cases projected to rise sharply by 2050, and precision medicine and advanced therapies expanding rapidly, the secure preservation and traceability of biospecimens have become fundamental to drug development and regulatory compliance.
What “good” looks like: infrastructure, validation and documentation
Turning these principles into reliable practice requires purpose-built infrastructure and rigorous quality systems. High-quality biorepositories share several key attributes.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.